

Patent

Attorney Docket No. 09,980516
IC10 Rec'd PCT/PTO 02 NOV 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Bergeron, Michel et al.
Serial No. :
Confirmation No. :
Filing Date : Herewith
For : Methods and Formulations for Targeting Infections Agents Bearing Host Cell Proteins

CERTIFICATION UNDER 37 CFR 1.8(a) and 1.10

I hereby certify that, on the date shown below, this correspondence is being:

Mailing

■ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Box PCT, Attn: DO/EO, Washington, D.C. 20231

37 CFR 1.8(a)

□ with sufficient postage as first class mail

37 CFR 1.10

■ As "Express Mail Post Office to Addressee" Mailing Label No. EL810083576US

Transmission

□ transmitted by facsimile to Fax No.: addressed to Examiner at the Patent and Trademark Office

Date: November 2, 2001

John B. Hawk

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97/98

In compliance with Applicant's duty of disclosure as set forth in 37 C.F.R. §1.56, listed on the attached equivalent to Form PTO-1449 are those patents and other publications known to the Applicant which may be considered material to the patentability of the claims of the above-captioned application.

The Applicant respectfully requests that the documents listed on the attached equivalent to Form PTO-1449 be considered by the Examiner, that these references be made of record in the present applicant, and that an initialed copy of the attached equivalent to Form PTO-1449 be returned to the undersigned in accordance with MPEP 609.

Respectfully submitted,

Kristine M. Strodthoff

Kristine M. Strodthoff
Registration No. 34259

Dated: November 2, 2001

P.O. ADDRESS:

WHYTE HIRSCHBOECK DUDEK S.C.
111 East Wisconsin Avenue, Suite 2100
Milwaukee, Wisconsin 53202
(414) 273-2100
Customer No.: 022202

Patent

Attorney

Docket No. GGD-31611-PCT-US

JC10 Rec'd PCT/PTO

09, 980516
02 NOV 2001

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Washington, D.C. 20231 INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Atty. Docket No.: GGD-31611-PCT-US	Serial No: Unknown
	Applicant: Michel Bergeron, et al.	Group Art Unit: Unknown
	Filing Date: Herewith	

U.S. PATENT DOCUMENTS

Examiner Initial		Patent Number	Issue Date	Patentee	U.S. Class	Sub-Class	Filing Date
	A1	5,013,556	05-07-91	Woodle et al.	424	450	10-20-89
	A2						

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial		Document Number	Publication Date	Country	Int'l Class	Sub-Class	Translation (Yes/No)
	B1	0 286 418 A1	12-10-88	EPO	A 61K	9/50	N/A
	B2	96/25147	08-22-96	WO	A61K	9/127	N/A
	B3	96/10399	04-11-96	WO	A61K	31/00	N/A
	B4	96/10585	04-11-96	WO	C07K	17/06	N/A

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial		
		DESORMEAUX A. ET AL.: "Targeting HIV with liposome encapsulated antivirals" ZBL. BAKT., vol. 282, April 1995 (1995-04), pages 225-231
		PHILLIPS N.C.: "Immunoliposome targeting to murine CD4+ leucocytes is dependent on immune status" IMMUNOL., vol. 152, 1994, pages 3168-3174
		DESORMEAUX A. ET AL.: "Liposomes as drug delivery system: a strategic approach for the treatment of HIV infection" LDRUG TARGETING, vol. 6, no. 1, 1998, pages 1-15

Examiner	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE Washington, D.C. 20231 INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Atty. Docket No.: GGD-31611-PCT-US	Serial No: Unknown
	Applicant: Michel Bergeron, et al.	Group Art Unit: Unknown
	Filing Date: Herewith	

Examiner Initial		
		MARUYAMA K. ET AL.: "Possibility of active targeting to tumor tissues with liposomes" ADV DRUG DELIV REVIEWS, vol. 40, 10 October 1999 (1999-10-10), pages 89-102
		MENEZES DE D E L ET AL.: "Cellular Trafficking and Cytotoxicity of Anti-CD19-Targeted Liposomal Doxorubicin In B Lymphoma Cells" JOURNAL OF LIPOSOME RESEARCH, US, MARCEL DEKKER, NEW YORK, vol. 9, no. 2, May 1999 (1999-05), pages 199-228
		LUNDBERG B. B. ET AL.: "Specific binding of sterically stabilized anti-B-cell immunoliposomes and cytotoxicity of entrapped doxorubicin" INT J PHARMAC, vol 205, September 2000 (2000-09), pages 101-108
		BESTMAN-SMITH J. ET AL.: "Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1" BIOCHIM BIOPHYS ACTA, vol. 1468, 29 September 2000 (2000-09-29), pages 161-174
		BESTMAN-SMITH J. ET AL.: "Targeting cell-free HIV and virally infected cells with anti HLA-DR immunoliposomes containing amphotericin B" AIDS, vol. 14, 10 October 2000 (2000-10-10), pages 2457-2465
		DUFRESNE I. ET AL.: "Targeting lymph nodes with liposomes bearing anti-HLA-DR Fab' fragments" BIOCHIM BIOPHYS ACTA, vol. 1421, 15 October 1999 (1999-10-15), pages 284-294
		ZELPHATI ET AL.: "Inhibition of HIV-1 Replication in Cultured Cells with Antisense Oligonucleotides Encapsulated in Immunoliposomes" ANTISENSE RESEARCH AND DEVELOPMENT, vol. 3, 1993, pages 323-338

Examiner	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	